When is it appropriate to start a long‑acting formulation of Adderall (mixed amphetamine salts)?

When to Start Long-Acting Adderall (Mixed Amphetamine Salts Extended-Release)

Start long-acting Adderall (MAS-XR) after establishing efficacy and optimal dosing with immediate-release formulations, or as initial therapy if once-daily dosing is preferred for compliance, privacy, or convenience—typically after baseline cardiovascular assessment and documentation of ADHD diagnosis.

Initial Treatment Strategy

The decision to start with long-acting versus immediate-release formulations depends on your clinical context:

Starting with Immediate-Release First (Traditional Approach)

This is the approach recommended by established guidelines 1. Begin with immediate-release mixed amphetamine salts at 2.5-5 mg once or twice daily, titrating by 2.5-5 mg weekly until optimal response is achieved 1, 2. Once you've identified the effective total daily dose (typically the sum of morning and noon doses), convert to the equivalent long-acting formulation 1.

• Rationale: Immediate-release allows faster titration, easier identification of optimal dosing, and quicker discontinuation if prohibitive side effects occur
• Conversion: Add the morning and noon immediate-release doses together to determine the long-acting dose 1
• Example: If a patient responds to 10 mg immediate-release twice daily (20 mg total), switch to 20 mg MAS-XR once daily

Starting with Long-Acting Formulation Directly (Modern Approach)

You can initiate treatment with long-acting Adderall as first-line therapy 2, 3, 4. The FDA label supports starting with 10 mg daily in patients ≥6 years, with weekly 5-10 mg increments up to 40 mg maximum 2.

• When to prefer this approach:
  • Adolescents who need privacy and want to avoid school-based dosing 1
  • Compliance concerns with multiple daily doses 1
  • Need for all-day coverage (12-hour duration) 4, 5, 6
  • Patient/family preference for once-daily dosing

Mandatory Pre-Treatment Requirements

Before starting any amphetamine formulation 1, 2:

1. Cardiovascular screening: Obtain baseline blood pressure, pulse, and careful cardiac history including family history of sudden death or ventricular arrhythmia 1
2. Baseline measurements: Height and weight 1
3. Tic assessment: Evaluate family history and clinically assess for motor/verbal tics or Tourette's syndrome 1, 2
4. Documentation: Prior treatments, psychosocial interventions, medication trials with doses, duration, response, and side effects 1

Age-Specific Considerations

Children (Ages 3-5 Years)

• Not recommended as first-line 7. Methylphenidate has stronger evidence in preschoolers
• If amphetamines are used: Start 2.5 mg daily, increase by 2.5 mg weekly 2
• Only for moderate-to-severe ADHD unresponsive to behavioral therapy 7

Children (Ages 6+ Years) and Adolescents

• Start 5 mg once or twice daily (immediate-release) or 10 mg daily (extended-release) 2
• Titrate by 5 mg weekly intervals 1, 2
• Maximum 40 mg/day 1, 2
• For adolescents, strongly consider starting with long-acting formulation to avoid in-school dosing and peer stigma 1

Adults

• Start 10 mg daily (long-acting) or 5 mg twice daily (immediate-release) 2
• Titrate by 5-10 mg weekly 1
• Maximum typically 40 mg/day, though some patients may require up to 60 mg/day for full-day coverage 1, 5
• Adults often need higher total daily doses because they require coverage for longer waking hours 1

Pharmacokinetic Advantages of Long-Acting Formulation

MAS-XR provides 4, 6:

• Onset: 1.5-2 hours post-dose 6
• Duration: 12 hours of coverage 4, 5, 6
• Mechanism: 50% immediate-release beads + 50% delayed-release beads (releasing ~4 hours later) 4
• Bioequivalence: MAS-XR 20 mg ≈ immediate-release 10 mg twice daily 4

Common Pitfalls to Avoid

1. Don't skip cardiovascular screening: Amphetamines are contraindicated with symptomatic cardiovascular disease, uncontrolled hypertension, or hyperthyroidism 1, 2
2. Don't use with MAOIs: Absolute contraindication 1, 2
3. Don't ignore substance abuse history: Use extreme caution or avoid in patients with stimulant abuse history unless closely supervised 1
4. Don't dose late in the day: Give in the morning to minimize insomnia 1, 2
5. Don't exceed maximum doses without clear documentation: If 40 mg/day is insufficient, consider alternative medications rather than pushing higher 1

Monitoring After Initiation

• Weekly during titration: Assess target symptoms, side effects (appetite, sleep, irritability, tics), vital signs 1
• Quarterly for adults: Blood pressure and pulse checks 1
• Each visit: Weight monitoring (objective measure of appetite suppression) 1
• Watch for: Peripheral vasculopathy, growth delays in children, emergence of tics, cardiovascular symptoms 2